



# Gel-One<sup>®</sup>

Cross-Linked  
Hyaluronate

- 91 day joint residency time<sup>2</sup>
- Lowest single injection treatment volume
- Zero reports of pseudosepsis to date<sup>3,4</sup>

Pure<sup>1</sup> & Simple

National Drug Code (NDC)	Trade Name	Federal Supply Schedule (FSS) Price	Vendor	CNT NO.
87541-0300-91	Hyaluronic Acid 10 mg/ml INJ	\$398.99	Zimmer US	V797D-40102

Our FSS price is loaded with the following wholesalers. When you place an order, please utilize the following account numbers:

**Cardinal Health Pharmacy:** #21382  
**McKesson Pharmacy:** #50745  
**ABC:** #10141568

Contact your Zimmer Biomet Representative, call **1-800-348-2759**



**ZIMMER BIOMET**  
Your progress. Our promise.™

1. Quality of product, including protein, bacterial endotoxin and DNA, is strictly controlled through manufacturing process performed by Seikagaku Corporation.
2. Animal study done by ADME & Tox. Research Institute, Sekisui Medical Co., Ltd. for Seikagaku Corporation. Data on file at Seikagaku Corporation. Animal studies are not necessarily indicative of clinical results.
3. V. Strand, et al. A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee. *Osteoarthritis and Cartilage*; 2012 (20), 350-356.
4. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm> April 18, 2016.

**Important Safety Information:** Before using Gel-One Hyaluronate, ask your patients if they are allergic to hyaluronan products, cinnamon, or products from birds such as feathers, eggs, and poultry. Gel-One Hyaluronate is only for injection into the knee, performed by a doctor or other qualified health care professional. Gel-One Hyaluronate injection should not be used in the presence of a skin disease or infection around the area where the injection will be given. Gel-One Hyaluronate has not been tested to show pain relief in joints other than the knee and for conditions other than OA. Gel-One Hyaluronate has not been tested in patients who are pregnant, mothers who are nursing, or anyone under the age of 21. Strenuous or pro-longed weight-bearing activities after treatment are not recommended. The effectiveness of repeat treatment cycles of Gel-One Hyaluronate has not been established. The side effects most commonly seen after injection of Gel-One Hyaluronate in the clinical trial were knee pain, swelling, and/or knee effusion. These reactions are generally mild and do not last long. For complete instructions for use, see the package insert and visit [www.zimmerbiomet.com](http://www.zimmerbiomet.com). Gel-One® is a registered trademark of Seikagaku Corporation.

Gel-One Hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to non-pharmacologic therapy, non-steroidal anti-inflammatory drugs (NSAIDs) or simple analgesics, e.g., acetaminophen.

This material is intended for health care professionals and the Zimmer Biomet sales force only. Distribution to any other recipient is prohibited. All content herein is protected by copyright, trademarks and other intellectual property rights owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated. This material must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.

For complete product information, including indications, contraindications, warnings, precautions, and potential adverse effects, see the package insert, [www.zimmerbiomet.com](http://www.zimmerbiomet.com), or contact your local Zimmer Biomet representative.

© 2016 Zimmer Biomet



**ZIMMER BIOMET**  
Your progress. Our promise.™